Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
International Journal of Clinical Pharmacy|October 1, 2024
Cost-effectiveness analysis of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of rearranged during transfection fusion-positive non-small cell lung cancer in the United StatesHongbin Yi, Yingdan Cao, Fenghao Shi, et al.
Frontiers in Pharmacology|November 4, 2022
Cost-effectiveness of edaravone dexborneol versus edaravone for the treatment of acute ischemic stroke in China: Based on the TASTE studyFenghao Shi, Zixuan He, Lin Wang, et al.
Frontiers in Oncology|September 17, 2025
Cost-effectiveness analysis of the combination of low-dose nivolumab with triple metronomic chemotherapy for advanced head and neck squamous cell carcinoma in ChinaYingdan Cao, Fenghao Shi, Xiaoxia Wei, et al.
International Journal of Clinical Pharmacy|July 11, 2024
Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United StatesYingdan Cao, Hongbin Yi, Fenghao Shi, et al.
Research Synthesis Methods|February 2, 2026
NMAsurv: An R Shiny application for network meta-analysis based on survival dataTaihang Shao, Mingye Zhao, Fenghao Shi, et al.
Advances in Therapy|July 11, 2020
Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival ModelMingjun Rui, Fenghao Shi, Ye Shang, et al.
Frontiers in Pharmacology|December 5, 2022
Economic evaluation of tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma in ChinaFenghao Shi, Zixuan He, Hang Su, et al.
Frontiers in Pharmacology|August 7, 2023
Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricingYena Gan, Fenghao Shi, He Zhu, et al.
International Journal of Clinical Pharmacy|February 26, 2024
Cost-effectiveness analysis of PD-1 inhibitors as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China: an economic evaluation based on network meta-analysisShuang Liu, Linbo Zhao, Fenghao Shi, et al.
Frontiers in Public Health|November 8, 2021
A Systematic Review of Methods and Study Quality of Economic Evaluations for the Treatment of SchizophreniaLuying Wang, Fenghao Shi, Xin Guan, et al.
Pageof 2